Metabolic & Weight Loss
GLP-1s and metabolic compounds driving the biggest clinical and community interest.
Tirzepatide: The Dual-Incretin Heavyweight, Examined
A clear-eyed look at tirzepatide — the dual GIP/GLP-1 agonist with one of the strongest human-trial records in metabolic medicine.
Survodutide (BI 456906): The Glucagon/GLP-1 Dual Agonist Built for the Liver
A plain-English, evidence-first look at survodutide: how its dual GLP-1/glucagon action works, what the trials show for weight and liver, and the real-world catches.
Semaglutide: The Evidence-First Guide for Self-Experimenters
A plain-English, evidence-led rundown of semaglutide: how it works, what the big trials actually showed for weight, glucose and heart risk, and the catches.
Evidence gap · The strongest evidence applies to specific licensed uses — type 2 diabetes, weight management, and cardiovascular risk in people with established heart disease — not to general wellness or optimisation. Trial benefits also depend on continued use and largely reverse after stopping.
Retatrutide: The Triple Agonist Pushing Weight Loss Past Everything Before It
An evidence-first look at retatrutide, the investigational GLP-1/GIP/glucagon triple agonist posting the largest weight-loss numbers seen in any incretin trial to date.
Mazdutide: The First GLP-1/Glucagon Dual Agonist, and What the Trials Actually Show
Mazdutide is a once-weekly GLP-1/glucagon dual agonist with strong phase 3 evidence (up to ~20% weight loss) — but it is China-only and largely untested elsewhere.
Cagrilintide: The Amylin Analogue Behind CagriSema
A plain-English, evidence-first look at cagrilintide — the long-acting amylin analogue, its trial record, doses studied, and why it is almost never used alone.
AOD-9604: The Fat-Loss Peptide That Failed Its Own Trial
AOD-9604 is a growth-hormone fragment with strong fat-loss data in animals — but its pivotal human obesity trial failed, and it was never approved as a medicine.
Adipotide: The Fat-Vessel Killer That Stalled in Humans
Adipotide melts white fat by destroying the blood vessels feeding it. Striking animal data, zero human efficacy evidence, and kidney toxicity that ended its development.